PDCD1LG2 and neoplasm: These in vivo findings align with the observations from clinical cohorts, demonstrating that while high levels of PD‐L2 on EV membranes promote tumour growth and progression, the presence of PD‐L2+EVs during anti‐PD‐1 therapy may reflect a tumour microenvironment that is more amenable to immune checkpoint blockade.